# Sanara MedTech Inc. (SMTI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $34.73, market value $319 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sanara MedTech Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.9×**. Each dollar of revenue is priced at 2.9×.
- **Price / book: 45.3×**. The shares trade at 45.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 25.2×**. Enterprise value is 25.2× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.4%** (5-yr avg -0.8%). Free cash flow equals 1.4% of the market value, above its five-year average of -0.8%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Gross margin: 93.0%**. Sanara MedTech Inc. keeps 93.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 10.0%**. 10.0% of revenue is left after running the business.
- **Net margin: -36.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -632.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 24.5%**. Return on all capital, debt included, is 24.5%: comfortably above what that capital costs.
- **Return on assets: -43.9%**. Each dollar of assets produces -43.9% of profit.

## Growth
- **Revenue growth (1 yr): 19.0%** (3-yr 31.0%/yr, 5-yr 45.9%/yr). Revenue grew 19.0% over the last year, against 45.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -282.5%**. Earnings per share fell 282.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 7.74**. Debt is 7.74 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 2.1×**. It would take 2.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 4.72**. A Z-score of 4.72 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Sanara MedTech Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (3 analysts). 3 analysts cover Sanara MedTech Inc.; the consensus is hold, with an average price target of $35.00 (+1% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 2.0%** (YTD 48.7%, 3-mo 54.8%). The shares are up 2.0% over twelve months including dividends.
- **From 52-week high: -3.1%** (116.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 77**. An RSI of 77 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.86** (volatility 60%). Beta of 0.86 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SMTI · Page: https://foliofundamentals.com/stocks/smti

Not investment advice.